Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG

Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv

Potent and selective H3 histamine receptor inverse agonist

Novel inhibitor of EPHX2 (epoxide hydrolase 2, alias soluble epoxide hydrolase or sEH), up-regulating cytoprotective genes and down-regulating proinflammatory cytokine production

Novel potent, metabolically stable and centrally penetrant PPARγ partial agonist

Novel competitive inhibitor of rTbIPMK with respect to Ins(1,4,5)P3

Novel selective non-imidazole histamine H 3 receptor antagonist

Novel AKT Inhibitor, Enhancing Anti-Tumor Effects in Combination with the MEK Inhibitor

Novel insulin-like growth factor 1 receptor inhibitor, binding to a novel region of the GRK active site cleft that could likely be exploited to achieve more selectivity

Novel inhibitor of T. brucei IPMK, partially inhibiting rTbIPMK activity

Inhibitor of insulin receptor, also tageting IGF-1R and ALK

Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway

Novel highly potent, reversible soluble epoxide hydrolase (sEH) inhibitor, exhibiting potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET, attenuating cigarette smoke-induced inflammation by both i

Novel S1P1 receptor agonist

Novel I-kappa-B kinase-3 (IKK3) inhibitor

Novel selective histamine H3 receptor antagonist

Specific ATPase competitive kinesin-5 inhibitor

Betulin derivative as antitumor agent

Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)

Novel potent and selective, SAM-competitive inhibitor of SMYD3

Novel human immune virus (HIV) maturation inhibitor

Novel inhbitor of protein kinase GRK1/2/5 and PKA